

Anti-IL-23a Reference Antibody (guselkumab)

Catalog # APR11175

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9NPF7
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	20730


Additional Information

Target/Specificity	IL-23a
Expression system	CHO


Protein Information

Name	IL23A
Synonyms	SGRF
Function	Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity (PubMed: 11114383). Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4 (PubMed: 29287995 , PubMed: 32474165 , PubMed: 33606986). This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A (PubMed: 12023369). In turn, participates in the early and effective intracellular bacterial clearance (PubMed: 32474165). Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells (PubMed: 17676044).
Cellular Location	Secreted. Note=Secreted upon association with IL12B
Tissue Location	Secreted by activated dendritic and phagocytic cells and keratinocytes. Also expressed by dermal Langerhans cells (at protein level).


Images



Anti-IL-23a Reference Antibody (guselkumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-IL-23a Reference Antibody (guselkumab) is 98.97%, determined by SEC-HPLC.



Immobilized huIL-23p19-N-His&huIL-12p40 at 2 µg/mL can bind guselkumab, EC₅₀= 0.02195 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.